News
-
-
PRESS RELEASE
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
Telomir Pharmaceuticals reports preclinical findings showing Telomir-1 reduces PSA levels in prostate cancer cells, indicating potential treatment response. CEO and scientific perspectives highlighted -
-
-
-
PRESS RELEASE
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
New data from Telomir Pharmaceuticals show Telomir-1 effectively modulates iron levels in human keratinocytes, key for its epigenetic mechanism. Telomir-1 provides strong intracellular iron reduction surpassing Deferoxamine -
-
PRESS RELEASE
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
Telomir Pharmaceuticals reports new findings on Telomir-1's impact on CASP8 and GSTP1 genes, highlighting potential in cancer therapy through DNA methylation modulation -
-
PRESS RELEASE
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
Telomir Pharmaceuticals strengthens global IP rights with acquisition of TELI Pharmaceuticals to expand shareholder contributions and advance investigational therapy, Telomir-1
